The event was part of President Macron’s official visit to Viet Nam, at the invitation of President Luong Cuong. This visit has particular significance, as it follows the elevation of Viet Nam–France relations to a Comprehensive Strategic Partnership in October 2024 during the official visit to France by General Secretary To Lam.
The announcement of the cooperation agreement between VNVC and Sanofi on vaccine production technology transfer is a clear testament to the mutual trust and shared commitment to advancing collaboration in vital sectors of the global era, such as health and healthcare.
This agreement marks a concrete step in implementing strategic cooperation between the two nations, laying the groundwork for bilateral development in the health sector beyond trade and human resource training, expanding into research cooperation, technology transfer, and the production of high-tech vaccines.
Under the agreement, VNVC and Sanofi will gradually implement the transfer of technology to manufacture several of Sanofi’s key vaccines widely used in Viet Nam.
Sanofi will also support VNVC in training human resources and ensuring quality management in vaccine research and production.
According to Ngo Chi Dung, as the Vietnamese Party and State are creating the most favourable conditions for private sector development, especially in international cooperation in science and technology, this partnership with Sanofi, one of the world’s leading vaccine manufacturers, is of critical importance. It will enable VNVC in particular, and the Vietnamese vaccine production industry in general, to rapidly enhance its production capacity and deliver world-class “Made in Viet Nam” vaccines.
Sanofi currently supplies tens of millions of high-quality vaccine doses for the Viet Nam, including the 6-in-1 Hexaxim, 4-in-1 Tetraxim, 3-in-1 Adacel for diphtheria, pertussis, and tetanus, Japanese encephalitis vaccine Imojev, rabies vaccine Verorab, meningococcal vaccine Menactra, hepatitis A vaccine Avaxim, quadrivalent flu vaccine Vaxigrip Tetra, and typhoid vaccine Typhim VI.
